HPC
KIN

HM Payson & Co’s Kindred Biosciences, Inc. KIN Stock Holding History

HM Payson & Co’s Portfolio KIN Stock Details KIN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-9,090
Closed -$45K – 1208
2021
Q1 		$45K Buy
+9,090
New +$43.9K ﹤0.01% 622

Other funds holding KIN

PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

HM Payson & Co's KIN Position: Q2 2021 in Review

HM Payson & Co sold out of Kindred Biosciences, Inc. (KIN) in Q2 2021, closing a stake of 9,090 shares — an estimated $45K sold.

HM Payson & Co first reported a position in KIN in Q1 2021 and held it in 1 quarter. The position peaked at $45K in Q1 2021. 87 funds tracked by Wall St. Rank hold KIN as of Q2 2021.

  • HM Payson & Co reported no remaining Kindred Biosciences, Inc. position as of Q2 2021 after selling out during the quarter.
  • HM Payson & Co sold 9,090 Kindred Biosciences, Inc. shares in Q2 2021, an estimated $45K.
  • HM Payson & Co first reported a position in Kindred Biosciences, Inc. in Q1 2021 and held it in 1 quarter.
  • HM Payson & Co's Kindred Biosciences, Inc. position peaked at $45K in Q1 2021.
  • 87 funds tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q2 2021.

Based on HM Payson & Co's 13F filing for Q2 2021, filed 17 Aug 2021.